Projecting future drug expenditures - 2004

American Journal of Health-System Pharmacy

Volumn 61, Issue 2, 2004, Pages 145-158

  Hoffman, James M ^a   Shah, Nilay D ^b,c   Vermeulen, Lee C ^a,b,d   Hunkler, Robert J ^e   Hontz, Karrie M ^e  

^a University of Wisconsin Health   (United States)

^b UWHC   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e IQVIA   (United States)

Author keywords

Costs; Drug use; Economics; Hospitals; Patents

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; AMIODARONE; BOTULINUM TOXIN B; CARBOPLATIN; CASPOFUNGIN; CEFTRIAXONE; CHICKENPOX VACCINE; DOCETAXEL; ENOXAPARIN; EPTIFIBATIDE; FLUCONAZOLE; GEMCITABINE; GENERIC DRUG; INFLIXIMAB; IOHEXOL; IRINOTECAN; LEUPRORELIN; LEVOFLOXACIN; NEW DRUG; ONDANSETRON; PARICALCITOL; PNEUMOCOCCUS VACCINE; PROPOFOL; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TRASTUZUMAB; UNINDEXED DRUG; ZOLEDRONIC ACID;

DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG USE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL COST; HUMAN; MEDICARE; OUTPATIENT CARE; PATENT; PHARMACY; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; ECONOMICS; FORECASTING; HOSPITAL PHARMACY; OUTPATIENT DEPARTMENT; PRESCRIPTION; STATISTICS; UNITED STATES;

AMBULATORY CARE FACILITIES; DRUG APPROVAL; DRUG COSTS; FORECASTING; HUMANS; PHARMACY SERVICE, HOSPITAL; PRESCRIPTIONS, DRUG; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 1842539509     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.2.145     Document Type: Review

References (92)

1. Centers for Medicare and Medicaid Services. www.cms.gov/statistics/nhe/ (accessed 2003 Aug 12).
2. Strunk BC, Ginsburg PB. Tracking health care costs: trends stabilize but remain high in 2002. Health Aff. 2003; 22:W266-74.
3. Heffler S, Smith S, Keehan S et al. Trends-health spending projections 2002-2012. Health Aff. 2003; 22:W54-65.
4. Kaiser Family Foundation. 2003 Employer health benefits survey September, 2003. www.ktt.org (accessed 2003 Sep 9).
5. Goetghebeur MM, Forrest S, Hay JW. Understanding the underlying drivers of inpatient cost growth: a literature review. Am J Manag Care. 2003; 9:SP3-12.
6. Hay JW. Hospital cost drivers: an evaluation of 1998-2001 state-level data. Am J Manag Care. 2003; 9:SP13-24.
7. Centers for Medicare and Medicaid Services. Health care industry market update: acute care hospitals. http://cms.hhs.gov/reports/hcimu/hcimu_07142003. pdf (accessed 2003 Sep 16).
8. American Hospital Association. Trends affecting hospitals and health-systems, TrendWatch chartbook. www.hospitalconnect.com/ahapolicyforum/ trendwatch/chartbook2003.html (accessed 2003 Oct 30).
9. IMS Health National Sales Perspectives. Analysis conducted by the authors.
10. IMS Health National Prescription Audit. Analysis conducted by the authors.
11. Kumar P, Zaugg A. IMS review: steady but not stellar. Med Mark Media. 2003; 38:50-63.
12. Shah ND, Hoffman JM, Vermeulen LC et al. Projecting drug expenditures - 2003. Am J Health-Syst Pharm. 2003; 60:137-49.
13. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized control trial. JAMA. 2002; 288:321-33.
14. 2002 Drug trend report. St. Louis: Express Scripts; 2003 Jun.
15. 2003 Drug trend report. Medco Health; 2003 May.
16. Weir HK, Thun MJ, Hankey BF et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003; 95:1276-99.
17. FDA faster approval times for 2002 NMEs aided by resubmissions. FDC Rep. 2003; Jan 6.
18. Kaufman M. Decline in new drugs raise concerns: FDA approvals are lowest in a decade. Wash Post. 2002; Nov 18:A1.
19. Pollack A. Despite billions for discoveries, pipeline of drugs is far from full. N Y Times. 2002; Apr 19:C1.
20. Dyer G. Anaemic patient needs to take its medicine: investors have fallen out of love with an industry with fewer products in the pipeline. Financ Times. 2003; Apr 16:2.
21. Center for Drug-Evaluation and Research. 2002 Report to the nation: improving public health through drugs. www.fda.gov/cder/reports/rtn/2002/ Rtn2002.pdf (accessed 2003 Sep 15).
22. Davis J, ed. 2002 - The year in review. Scrip World Pharm News. 2003; Feb 12:2-3.
23. Pharma pipelines filling, firms say; new fear is "bottleneck" in early stage. FDC Rep. 2003; Apr 21:20.
24. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003; 22:151-85.
25. Public Citizen. Rebuttals to PhRMA responses to the Public Citizen report "Rx R&D myths: the case against the drug industry's R&D 'scare card.'" www.citizen.org/congress/reform/drug_industry/articles.cfm?ID=6514 (accessed 2003 Jul 30).
26. Public Citizen. Rx R&D myths: the case against the drug industry's R&D "scare card." www.citizen.org/documents/ACFDC.PDF (accessed 2003 Jul 30).
27. Frank RG. New estimates of drug development costs. J Health Econ. 2003; 22:325-30. Editorial.
28. Food and Drug Administration Center for Drug Evaluation and Research. New drug approval reports. www.fda.gov/cder/rdmt/(accessed 2003 Jul 30).
29. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics. 2002; 20(suppl 3):1-10.
30. Abboud L, McGinley L. FDA chief embarks on novel mission: cut drug costs-economist McClellan hopes to streamline approval process, but must tread carefully. Wall St J. 2003; Apr 16:A4.
31. Adams C. FDA to give advice on avoiding approval delays. Wall St J. 2003; Jan 31:B5.
32. Rowland C. FDA chief looks to speed diabetes, obesity drugs. Boston Globe. 2003; Jun 4:A1.
33. Food and Drug Administration. NCI and FDA announce joint program to stream-line cancer drug development. www. fda.gov/bbs/topics/news/2003/new00912. html (accessed 2003 Aug 4).
34. Abboud L. FDA gives early approval to cancer drug-action is part of new effort to get treatments to patients faster; factoring in what doctors think. Wall St J. 2003; May 14:D1.
35. Top 10 areas of research: report on the most popular fields of drug development. Med Ad News. 2003; 22:S22.
36. Francis CW, Davidson BL, Berkowitz SD et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann Intern Med. 2002; 137:648-55.
37. Glynn O. The EXPRESS study: preliminary results. Int J Clin Pract. 2003; 57:57-9.
38. Eriksson BI, Bergqvist D, Kalebo P et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the MEHTRO II randomized trial. Lancet. 2002; 360:1441-7.
39. Heit JA, Colwell CW, Francis CW et al., for the AstraZeneca Arthroplasty Study Group. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a Phase II dose finding study. Arch Intern Med. 2001; 161:2215-21.
40. Eriksson H, Wahlander K, Lundstrom T et al. Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial. Blood. 2002; 100:297. Abstract.
41. Huisman MV, for the THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. J Thromb Haemost. 2003; 1(suppl 1): OC003. Abstract.
42. Halperin JL, for the SPORTIF III and V Investigators. Ximelagatran compared with warfarin for the prevention of stroke and systematic embolic events in patients with nonvalvular atrial fibrillation: rationale, objectives, design and organization of two long-term clinical trials (SPORTIF III and V). Blood. 2002; 100:3976. Abstract.
43. Atrial fibrillation; oral anticoagulant studied as alternative to warfarin for stroke prevention. Drug Week. 2003; May 2:21.
44. Hopfner R. Ximelagatran (AstraZeneca). Curr Opin Invest Drugs. 2002; 3:246-51.
45. Panning CA, DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy. 2003; 23:183-9.
46. Van Noord JA, Bantje TA, Eland ME et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000; 55:289-94.
47. Vincken W, van Noord JA, Greefhorst AP et al., for the Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002; 19:209-16.
48. Nektar reports results on inhaled-insulin testing. N Y Times. 2003; Jun 17:C3.
49. Roger EM. Diffusion of innovations. 4th ed. New York: Free Press; 1995.
50. Berwick DM. Disseminating innovations in health care. JAMA. 2003; 289:1969-75.
51. Tamblyn R, McLeod P, Hanley JA et al. Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Care. 2003; 41:895-908.
52. Kocs D, Fendrick AM. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care. 2003; 9:393-400.
53. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108:184-90.
54. Abramowicz M, ed. Omalizumab (Xolair): an anti-IgE antibody for asthma. Med Lett Drugs Ther. 2003; 45:67-8.
55. Lutz K. Asthma drug has promise and big price. Boston Globe. 2003; Jun 19:A1.
56. Abramowicz M, ed. Enfuvirtide (Fuzeon) for HIV infection. Med Lett Drugs Ther. 2003; 45:49-50.
57. Abramowicz M, ed. Bortezomib (Velcade) for multiple myeloma. Med Lett Drugs Ther. 2003; 45:57-8.
58. AstraZeneca prices Iressa at 25% discount to Gleevec; launch in May. FDC Rep. 2003; May 12:5.
59. Vollmer S. Patients, doctors cool to Fuzeon. Raleigh News Obs. http://newsobserver.com/business/v-print/story/2874119p-2650295c.html (accessed 2003 Sep 16).
60. Emend package insert. Whitehouse Station, NJ: Merck; 2003.
61. Shook D. A shock to Lilly's system. www.businessweek.com/bwdaily/dnflash/ mar2002/nf2002037_2428.htm (accessed 2003 Aug 18).
62. Xigris package insert. Indianapolis, IN: Eli Lilly; 2002.
63. Seigel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med. 2002; 347:1030-4.
64. Angus DC, Linde-Zwirble WT, Clermont G et al., for the PROWESS Investigators. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med. 2003; 31:1-11.
65. Manns BJ, Lee H, Doig CJ et al. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med. 2002; 347:993-1000.
66. Abraham E, Reinhart K, Opal S et al., for the OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003; 290:238-47.
67. Lebbos J, Bradsher J, Kirkpatrick P. Drotrecogin alpha (activated). Nat Rev Drug Discov. 2003; 2:13-4.
68. Important facts and figures. Med Ad News. 2003; 22:10.
69. Barr Cipro generic takes 50% share; erosion slow under Bayer deal. FDC Rep. 2003; Aug 11:18.
70. Aventis Lovenox generics defense includes re-issuance of patent. FDC Rep. 2003; May 5:10.
71. FDA clears 79 first generics in 2002 during record-breaking year for ANDAs. FDC Rep. 2003; 2002 year-in-review: 13.
72. Food and Drug Administration. FDA acts to lower drug prices by implementing new regulation to improve generic drug competition. www.fda.gov/oc/initiatives/generics/fs_rule.html (accessed 2003 Sep 8).
73. Pear R, Toner R. Senate votes to give consumers faster access to generic drugs, amending Medicare bill. N Y Times. 2003; Jun 20:A18.
74. Food and Drug Administration. FDA's new regulation to speed access to lower cost generic drugs about to take effect. www.fda.gov/bbs/topics/NEWS/2003/ NEW00932.html (accessed 2003 Aug 12).
75. Vastag B. FDA to speed generics. JAMA. 2003; 290:324. News.
76. BIO petition opposes generic insulin, HGH; asks FDA to open public debate. FDC Rep. 2003; Apr 28:13-4.
77. Rowland C. No simple generic answer. Biotech industry challenging potential review process for biogenerics. Boston Globe. 2003; Jul 16:C1.
78. Langley A. Engineered drugs open new issue of regulation as patents expire. N Y Times. 2003; Aug 9:C1.
79. Generic biologics cannot use Waxman/Hatch as model, ex-FDAer Siegel says. FDC Rep. 2003; Jan 27:16-7.
80. Iglehart JK. Prescription drug coverage for Medicare beneficiaries. N Engl J Med. 349; 10:923-5.
81. Toner P, Pear R. Compromise seen as harder to find on Medicare drugs. N Y Times. 2003; Jul 13:A1.
82. Stolberg GS, Harris G. Industry fights to put imprint on drug bill. N Y Times. 2003; Sep 5:A1.
83. Fed Regist. 2003; 68:47966-48248.
84. Lueck S. Medicare payments to be boosted; in boon to biotech industry, lawmakers agree to cover new outpatient drugs. Wall St J. 2003; Sep 10:D9.
85. Association of Community Cancer Centers. Congressional conferees agree to include OPPS remedies in final Medicare legislation. www.accc-cancer.org/news/ oppsremedies.asp (accessed 2003 Sep 11).
86. AWP reform: competitive bidding option could save the most, CMS says. FDC Rep. 2003; Aug 21:21.
87. American Society of Clinical Oncology. ASCO comments on CMS AWP proposal. www.asco.org/asco/downloads/101003_Alert_-_ASCO_Comments.pdf (accessed 2003 Oct 30).
88. Perez-Pena R. 22 States limiting doctors' latitude in Medicaid drugs. N Y Times. 2003; Jun 16:A1.
89. Washington State preferred drug list expected to save $54 million. FDC Rep. 2003; Aug 25:23.
90. Freudenheim M. States organizing a non-profit group to cut drug costs. N Y Times. 2003; Jan 14:A1.
91. Tieman J. Maine's right prescription; justices approve controversial drug-price. Mod Healthc. 2003; May 26:6.
92. Mooney C. Remember the Maine; a small state casts fear in the heart of big pharma. Am Prospect. 2003; Sep:18.